Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585726 · ClinicalTrials.gov registry record · NA
Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)
A NA study, sponsored by Lake Washington Vascular.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT02585726: Completed NA study, sponsored by Lake Washington Vascular.
NCT02585726 is a NA study that has completed, run by Lake Washington Vascular. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02585726, a NA study, has completed, sponsored by Lake Washington Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS).
Primary Outcome
CC of the PTVS as assessed by duplex ultrasound 1 month after the index procedure.
Interventions
- DEVICE SP-402 VenaSeal™ Closure System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-07 |
| Phase | NA |
What the finished NCT02585726 record still lists
NCT02585726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which SP-402 VenaSeal™ Closure System is the first listed.
NCT02585726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02585726 about?
NCT02585726 is a clinical study titled "Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)". The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic veno...
What is the current status of trial NCT02585726?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-10. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02585726?
The interventions under investigation include: SP-402 VenaSeal™ Closure System (DEVICE).
Who is sponsoring clinical trial NCT02585726?
This trial is sponsored by Lake Washington Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02585726's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia